New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 12, 2012
16:38 EDTWXWuXi PharmaTech sees Q4 revenue $121M-$124M, consensus $124.92M
Sees Q4 operating margin of about 17.0% GAAP, about 20.0% non-GAAP.
News For WX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 21, 2015
19:20 EDTWXWuXi consortium to acquire Ambrx
A consortium consisting of entities affiliated with Fosun Pharmaceutical, HOPU Investments, CEL Healthcare Fund, and WuXi PharmaTech (WX) announced that it has signed a merger agreement to acquire Ambrx (AMBX). The transaction is expected to close in Q2. Chairman Chen Qiyu of Fosun Pharma said, "This joint acquisition will result in great synergy with [our] current R&D system and platform. Under the help of Fosun Pharma, Ambrx's business expanding in China will enable Chinese patients to get faster access to innovative therapeutic drugs." Ge Li, CEO of Wuxi, remarked, "This transaction will allow WuXi to broadly access Ambrx's best-in-class ADC platform and biologics development capabilities."
May 13, 2015
16:35 EDTWXWuXi PharmaTech backs FY15 non-GAAP EPS view $1.73-$1.78, consensus $1.76
Subscribe for More Information
16:33 EDTWXWuXi PharmaTech reports Q1 EPS 36c, consensus 32c
Reports Q1 revenue $180.0M, consensus $174.15M.
15:04 EDTWXNotable companies reporting after market close
Subscribe for More Information
08:06 EDTWXWuXi PharmaTech formes special committee to evaluate non-binding proposal
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use